RxDoctor Payments Data

Linda Bang, MD

Internal Medicine · Plano, TXNPI 1447243688

Payments from drug & device makers

$9,127in general payments, 2019–2025

Across 563 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Boehringer Ingelheim$708
  • Amarin Pharma, Inc.$622
  • Lilly USA, LLC$536
  • GSK$471
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$9,127100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,127 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$135,138
Medicare patients
141
Services billed
4,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$54,554
Breo ElliptaFluticasone/Vilanterol15$11,359
ArexvyRsvpref3 Antigen/As01e/Pf28$8,593
ShingrixVaricella-Zoster Ge/As01b/Pf16$3,505
Rosuvastatin Calcium210$2,380
Ezetimibe75$1,455
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,368
SynthroidLevothyroxine Sodium17$1,281
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide16$1,144
Losartan Potassium88$1,087
Metformin Hcl ErMetformin Hcl105$1,071
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf15$1,058
Amlodipine Besylate135$844
Atorvastatin Calcium93$804
Valsartan32$757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,404$54,55440 claims
GSKBreo Ellipta, Arexvy, Shingrix$471$23,45759 claims
AbbVieSynthroid$1,279$1,28117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →